Dice Therapeutics shares leaped on positive data for its lead drug candidate. What comes next?

The world's best-selling drug begins losing patent protections next year. AbbVie's revenue could take years to recover.

Biotech stocks remain undervalued, but investors could start building a position.

The FDA approval of Sotyktu for psoriasis has both ignited and dampened prospects for smaller biotech stocks.

Bristol Myers Squibb received good news from the FDA, but only enough to put a key resistance level in play. Here's the level it needs to clear.

Stocks finished higher after snapping a three-week losing streak as the dollar continues to slide against its global currency peers.

“We believe Sotyktu is a breakthrough in the treatment of patients suffering from moderate-to-severe plaque psoriasis," said Bristol Myers' chief medical officer Samit Hirawat.

Competitive drug prices are great for consumers. Turns out, they're good for industry, too.

U.S. stocks finished the session higher, reversing two consecutive days of losses, as investors looked past Pelosi's Taiwan visit and ahead to key economic data.

If you're planning to visit Magic Kingdom, Epcot, Hollywood Studios, or Animal Kingdom, you need to know these things first.

After a wild period before and after the official purchase of Twitter, the company's new CEO settles on a request he has of the microblogging site's users.

Covid caused a long dark period for the cruise industry from March 2020 through July 2021. Michael Bayley talks about what that time was like.